# Ares Capital Corp: overview ARCC · Nasdaq · CIK 1287750 · [Other](/sectors/other.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/arcc.md) · [Financials](/companies/arcc/financials.md) · [Filings](/companies/arcc/filings.md) · [Insiders](/companies/arcc/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | [0.36](/filings/0001628280-26-027688.md) | [0.52](/filings/0001628280-26-050307.md) | [0.57](/filings/0001628280-26-067383.md) | not reported | [0.13](/filings/0001628280-26-027688.md) | [0.24](/filings/0001628280-26-050307.md) | [0.44](/filings/0001628280-26-067383.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL not reported. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. ## Last five fiscal years | Line item | Unit | FY (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [3.51](/filings/0001287750-24-000011.md) | [1.19](/filings/0001287750-25-000007.md) | [2.68](/filings/0001287750-26-000006.md) | [2.44](/filings/0001287750-26-000006.md) | [1.86](/filings/0001287750-26-000006.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL not reported. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/arcc/insiders.md) | Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing | | --- | --- | --- | --- | ---: | ---: | ---: | --- | | 2026-10-28 | [Henson Mary Beth](/insiders/1916183.md) | Director | Purchase (P) | 2,500 | $18.46 | $46.1k | [Form 4](/filings/0001628280-26-068348.md) | ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $315.4m | 17,022,990 | | Added +668,630 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $255.3m | 13,778,805 | | Reduced −537,740 | | [VAN ECK ASSOCIATES CORP](/funds/869178.md) | 2026-06-30 | $246.6m | 13,306,095 | | Added +2,418,984 | | [STRS OHIO](/funds/820478.md) | 2026-06-30 | $197.5m | 10,657,085 | | Added +157,085 | | [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $165.6m | 8,935,191 | | Reduced −200,263 | | [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $145.3m | 7,850,659 | | Added +156,109 | | [Generali Asset Management SPA SGR](/funds/2046751.md) | 2026-06-30 | $139.9m | 7,547,995 | | Unchanged | | [Legal & General Group Plc](/funds/764068.md) | 2026-06-30 | $120.5m | 6,510,302 | | Added +535,294 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $109.1m | 5,886,022 | | Reduced −1,420,322 | | [WELLS FARGO & COMPANY/MN](/funds/72971.md) | 2026-06-30 | $82.2m | 4,437,109 | | Reduced −49,497 | ## Recent filings [All 1,333 filings](/companies/arcc/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-27 | 06:20 ET | [10-Q](/filings/0001628280-26-067383.md) | Quarterly report, period 2026-09-30 | 0001628280-26-067383 | | 2026-10-27 | 06:14 ET | [8-K](/filings/0001628280-26-067382.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-067382 | | 2026-10-27 | 06:12 ET | [8-K](/filings/0001104659-26-118958.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-118958 | | 2026-09-15 | 16:05 ET | [8-K](/filings/0001104659-26-107911.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-107911 | | 2026-08-14 | 16:37 ET | [8-K](/filings/0001628280-26-057167.md) | 5.07 Shareholder vote results | 0001628280-26-057167 | | 2026-07-29 | 20:51 ET | [10-Q](/filings/0001628280-26-050307.md) | Quarterly report, period 2026-06-30 | 0001628280-26-050307 | | 2026-07-29 | 20:33 ET | [8-K](/filings/0001628280-26-050303.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-050303 | | 2026-07-22 | 17:23 ET | [8-K](/filings/0001104659-26-085912.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001104659-26-085912 | | 2026-06-22 | 16:20 ET | [8-K](/filings/0001628280-26-044648.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001628280-26-044648 | | 2026-06-08 | 20:52 ET | [8-K](/filings/0001628280-26-041366.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-041366 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001287750-26-000006.md), filed Feb 4, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1287750 - Tickers: ARCC - Exchange: Nasdaq - SIC code: not reported - State of incorporation: MD - Filer category: Large accelerated filer Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 19:05 ET. No prices; not investment advice.